Kit for detecting chlamydia pneumoniae IgM antibody

Abstract

The invention relates to a kit for detecting Chlamydia pneumoniae IgM antibody, and belongs to a medical detection reagent. The kit provided by the invention comprises a microplate coated with avidin, a biotinylated chlamydia pneumoniae antigen, horseradish peroxidase labelled anti-human IgM and a chemiluminescence substrate. According to the invention, the microplate is coated with avidin and the biotinylated antigen is indirectly coated through an avidin-biotin system. The invention provides convenience to amplify production and monitor the production process, avoids defects of big activity loss and cockamamie process optimization by directly coating a solid phase, and simultaneously ensures the stability among each batch.

Description

technical field

[0001] The invention relates to a medical detection reagent, in particular to a kit for detecting IgM antibody of Chlamydia pneumoniae. Background technique

[0002] Chlamydia pneumoniae (Cpn) is a strict eukaryotic intracellular parasitic prokaryotic microorganism identified in 1989, and has been renamed Chlamydophila pneumoniae (Chlamydophila pneumoniae, Cpn), together with Chlamydia psittaci, Chlamydia abortus, Chlamydia guinea pigs, Chlamydia cats, and Chlamydia mammals together form the genus Chlamydia. The CPn genome is about 1.2Mbp in size, and consists of 21 Pmp genes, a type III secretory virulence factor system, 3 serine / threonine protein kinases, and 2 phospholipase-D-like protein genes.

[0003] Cpn infection is very common and distributed worldwide, mainly causing respiratory tract infections in humans, which is positively correlated with population density, and mostly exists in the form of recessive and persistent infections in clinical practic...

Examples

Embodiment 1

[0015] Embodiment 1 kit preparation method of the present invention

[0016] 1, the kit of the present invention comprises:

[0017] 1) Chlamydia pneumoniae IgM positive control; 2) Chlamydia pneumoniae IgM negative control; 3) Chlamydia pneumoniae IgM calibrator; 4) microwell plate coated with avidin; 5) biotinylated Chlamydia pneumoniae antigen; 6) anti-human IgM enzyme marker; 7) 20-fold concentrated washing solution; and 8) chemiluminescence substrate solution.

[0018] Wherein, the microporous plate is a microporous strip with 24, 48 or 96 holes;

[0019] Anti-human IgM is goat anti-human IgM polyclonal antibody, rabbit anti-human IgM polyclonal antibody or mouse anti-human IgM monoclonal antibody;

[0020] Enzyme is horseradish peroxidase;

[0021] Chemiluminescence substrate solution: A solution and B solution.

[0022] 2, the preparation method of No. I kit of the present invention:

[0023] Prepare the positive control with Chlamydia pneumoniae IgM positive serum...

Embodiment 2

[0071] Embodiment 2. Comparative test of the kit chemiluminescent substrate of the present invention and the commercially available chemiluminescent substrate

[0072] Control kit: the same as the kit in Example 1, except that the chemiluminescent substrate solution (purchased from Huzhou Yingchuang Biotechnology Co., Ltd.) was used as a commercially available chemiluminescent substrate.

[0073] The test samples in step 1 were 254 samples of respiratory tract infection and 358 blood samples of healthy people in Example 1.

[0074] The detection operation steps are the same as those in Step 3 of Example 1.

[0075] The results are shown in Table 4.

[0076] Table 4. No. I kit chemiluminescent substrate of the present invention is compared with the chemiluminescent substrate sold in the market

[0077]

[0078] The data described in Table 4 shows that the positive coincidence rate of the No. I kit chemiluminescent substrate of the present invention and the comparative chem...

technical field

[0001] The invention relates to a medical detection reagent, in particular to a kit for detecting IgM antibody of Chlamydia pneumoniae. Background technique

[0002] Chlamydia pneumoniae (Cpn) is a strict eukaryotic intracellular parasitic prokaryotic microorganism identified in 1989, and has been renamed Chlamydophila pneumoniae (Chlamydophila pneumoniae, Cpn), together with Chlamydia psittaci, Chlamydia abortus, Chlamydia guinea pigs, Chlamydia cats, and Chlamydia mammals together form the genus Chlamydia. The CPn genome is about 1.2Mbp in size, and consists of 21 Pmp genes, a type III secretory virulence factor system, 3 serine / threonine protein kinases, and 2 phospholipase-D-like protein genes.

[0003] Cpn infection is very common and distributed worldwide, mainly causing respiratory tract infections in humans, which is positively correlated with population density, and mostly exists in the form of recessive and persistent infections in clinical practic...

Examples

Embodiment 1

[0015] Embodiment 1 kit preparation method of the present invention

[0016] 1, the kit of the present invention comprises:

[0017] 1) Chlamydia pneumoniae IgM positive control; 2) Chlamydia pneumoniae IgM negative control; 3) Chlamydia pneumoniae IgM calibrator; 4) microwell plate coated with avidin; 5) biotinylated Chlamydia pneumoniae antigen; 6) anti-human IgM enzyme marker; 7) 20-fold concentrated washing solution; and 8) chemiluminescence substrate solution.

[0018] Wherein, the microporous plate is a microporous strip with 24, 48 or 96 holes;

[0019] Anti-human IgM is goat anti-human IgM polyclonal antibody, rabbit anti-human IgM polyclonal antibody or mouse anti-human IgM monoclonal antibody;

[0020] Enzyme is horseradish peroxidase;

[0021] Chemiluminescence substrate solution: A solution and B solution.

[0022] 2, the preparation method of No. I kit of the present invention:

[0023] Prepare the positive control with Chlamydia pneumoniae IgM positive serum...

Embodiment 2

[0071] Embodiment 2. Comparative test of the kit chemiluminescent substrate of the present invention and the commercially available chemiluminescent substrate

[0072] Control kit: the same as the kit in Example 1, except that the chemiluminescent substrate solution (purchased from Huzhou Yingchuang Biotechnology Co., Ltd.) was used as a commercially available chemiluminescent substrate.

[0073] The test samples in step 1 were 254 samples of respiratory tract infection and 358 blood samples of healthy people in Example 1.

[0074] The detection operation steps are the same as those in Step 3 of Example 1.

[0075] The results are shown in Table 4.

[0076] Table 4. No. I kit chemiluminescent substrate of the present invention is compared with the chemiluminescent substrate sold in the market

[0077]

[0078] The data described in Table 4 shows that the positive coincidence rate of the No. I kit chemiluminescent substrate of the present invention and the comparative chem...

Images